On Friday, Sun Pharmaceutical Industries announced a licensing agreement with Takeda Pharmaceutical Company to commercialize a novel gastrointestinal drug in India. The Mumbai-based pharmaceutical giant has entered a non-exclusive patent licensing agreement with Takeda to market Vonoprazan tablets in 10 mg and 20 mg strengths in India.
About Vonoprazan
Vonoprazan is an innovative, orally active potassium-competitive acid blocker (PCAB) designed to treat reflux esophagitis and other acid peptic disorders.
“Sun Pharma is a leader in gastroenterology, and we are excited to introduce Vonoprazan in India under a non-exclusive patent license from Takeda,” said Kirti Ganorkar, CEO of Sun Pharma’s India Business. He added that this partnership underscores the company’s commitment to gastrointestinal health by providing patients and healthcare practitioners with a new treatment option for managing reflux esophagitis and other acid peptic disorders.
Gastroesophageal Reflux Disease (GERD) is prevalent in India, making this new treatment option particularly significant.
In November 2023, Vonoprazan received approval from the US FDA for the healing and maintenance of all grades of erosive esophagitis, providing relief from heartburn associated with erosive esophagitis. Additionally, it was approved for use in combination with amoxicillin and clarithromycin, or amoxicillin alone, for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Vonoprazan was discovered and developed by Takeda. It is approved in India for treating adults with reflux esophagitis and other acid peptic disorders.
Shares of Sun Pharma were trading up by 0.69% at ₹1,480.55 on the BSE.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
